These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39004952)

  • 1. Enzyme replacement therapy for hypophosphatasia-The current paradigm.
    Schindeler A; Ludwig K; Munns CF
    Clin Endocrinol (Oxf); 2024 Jul; ():. PubMed ID: 39004952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
    Kishnani PS; Rush ET; Arundel P; Bishop N; Dahir K; Fraser W; Harmatz P; Linglart A; Munns CF; Nunes ME; Saal HM; Seefried L; Ozono K
    Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.
    Scott LJ
    Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asfotase alfa therapy for children with hypophosphatasia.
    Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C
    JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270
    [No Abstract]   [Full Text] [Related]  

  • 5. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
    Hofmann C; Seefried L; Jakob F
    Drugs Today (Barc); 2016 May; 52(5):271-85. PubMed ID: 27376160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asfotase alfa has a limited effect in improving the bowed limbs in perinatal benign hypophosphatasia: A case report.
    Matsushita M; Mishima K; Nagata T; Kamiya Y; Imagama S; Kitoh H
    Clin Pediatr Endocrinol; 2021; 30(1):53-56. PubMed ID: 33446953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.
    Bowden SA; Foster BL
    Adv Exp Med Biol; 2019; 1148():279-322. PubMed ID: 31482504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophosphatasia: From Diagnosis to Treatment.
    Simon S; Resch H; Klaushofer K; Roschger P; Zwerina J; Kocijan R
    Curr Rheumatol Rep; 2018 Sep; 20(11):69. PubMed ID: 30203264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy.
    Bowden SA; Foster BL
    Drug Des Devel Ther; 2018; 12():3147-3161. PubMed ID: 30288020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia.
    Stürznickel J; Schmidt FN; von Vopelius E; Delsmann MM; Schmidt C; Jandl NM; Oheim R; Barvencik F
    Bone; 2021 Feb; 143():115794. PubMed ID: 33301963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Infantile Hypophosphatasia on Human Dental Tissue.
    Wölfel EM; von Kroge S; Matthies L; Koehne T; Petz K; Beikler T; Schmid-Herrmann CU; Kahl-Nieke B; Tsiakas K; Santer R; Muschol NM; Herrmann J; Busse B; Amling M; Rolvien T; Jandl NM; Barvencik F
    Calcif Tissue Int; 2023 Mar; 112(3):308-319. PubMed ID: 36414794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status Epilepticus due to Asfotase Alfa Interruption in Perinatal Severe Hypophosphatasia.
    Ogawa E; Shimura K; Yoshihashi H; Miyama S
    Pediatr Neurol; 2022 May; 130():4-6. PubMed ID: 35303588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphatasia: An overview For 2017.
    Whyte MP
    Bone; 2017 Sep; 102():15-25. PubMed ID: 28238808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophosphatasia: presentation and response to asfotase alfa.
    Alsarraf F; Ali DS; Almonaei K; Al-Alwani H; Khan AA; Brandi ML
    Osteoporos Int; 2024 Apr; 35(4):717-725. PubMed ID: 37993691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa.
    Seefried L; Rak D; Petryk A; Genest F
    Osteoporos Int; 2021 Dec; 32(12):2505-2513. PubMed ID: 34215909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa.
    Orimo H
    Ther Clin Risk Manag; 2016; 12():777-86. PubMed ID: 27274262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
    Kishnani PS; Del Angel G; Zhou S; Rush ET
    Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia.
    Dahir KM; Shannon A; Dunn D; Voegtli W; Dong Q; Hasan J; Pradhan R; Pelto R; Pan WJ
    J Bone Miner Res; 2024 Sep; 39(10):1412-1423. PubMed ID: 39135540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase's role in vitamin B
    Whyte MP; Zhang F; Mack KE; Wenkert D; Gottesman GS; Ericson KL; Cole JT; Coburn SP
    Bone; 2024 Apr; 181():117033. PubMed ID: 38307176
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.